Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Marchetti, Silvia;Rugge, Massimo;Fassan, Matteo;
2017

Abstract

Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.
2017
GUT
File in questo prodotto:
File Dimensione Formato  
Functional imaging ....pdf

accesso aperto

Tipologia: Published (publisher's version)
Licenza: Accesso gratuito
Dimensione 2.71 MB
Formato Adobe PDF
2.71 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3254611
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 41
social impact